AASLD/IDSA 2023: hepatitis C guidance update
International AASLD-IDSA Current
Hepatitis C Guidance 2023 Update: AASLD–IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Bhattacharya D, et al. Clin Infect Dis. 2023 (ciad319)
DOI 10.1093/cid/ciad319 · Summary checked against the source: 2026-11
The 2023 update in Clinical Infectious Diseases summarises changes since 2020 to the online AASLD/IDSA HCV guidance (hcvguidelines.org). Ratings use class I–III and level A–C.
At a glance
- Universal screening: HCV antibody at least once in every adult ≥18 and in every pregnancy, with reflex HCV RNA. [p. 2]
- Treat everyone with acute or chronic HCV, except those with short life expectancy that treatment can't change. [p. 4]
- Simplified treatment with minimal monitoring for treatment-naive adults without cirrhosis or with compensated cirrhosis: glecaprevir/pibrentasvir 8 weeks or sofosbuvir/velpatasvir 12 weeks. [p. 4–5]
- New algorithm for missed DAA doses (below). [Figure 2 · p. 3]
- DAA failure: sofosbuvir/velpatasvir/voxilaprevir 12 weeks is the main retreatment. [I, A · p. 8]
- Children from age 3: glecaprevir/pibrentasvir 8 weeks or sofosbuvir/velpatasvir 12 weeks. [I, B · p. 10]
Missed doses during DAA therapy
flowchart TD
A["Treatment-naive, no cirrhosis or compensated cirrhosis,<br/>on G/P or SOF/VEL, misses doses"] --> B{"How long on<br/>treatment?"}
B -->|"<28 days"| C{"Days missed"}
B -->|"≥28 days"| D{"Consecutive<br/>days missed"}
C -->|"≤7"| C1["Restart now; complete the<br/>originally planned course"]
C -->|"≥8"| C2["Restart now (before HCV RNA result)<br/>HCV RNA same day if possible<br/>Undetectable: complete planned dosage<br/>(+4 weeks if genotype 3 or cirrhosis)<br/>Positive (>25 IU/mL) or not done: extend by 4 weeks"]
D -->|"≤7"| D1["Restart now; complete the<br/>originally planned course"]
D -->|"8–20"| D2["Restart now; HCV RNA same day if possible<br/>Undetectable: complete planned dosage<br/>(+4 weeks if genotype 3 or cirrhosis)<br/>Positive: stop and retreat"]
D -->|"≥21"| D3["Stop; check SVR12<br/>Retreat if not achieved"]
Adapted from AASLD/IDSA 2023 Figure 2 [p. 3]. "Complete planned dosage" means giving the total number of pills: e.g. 10 missed days on an 8-week course extends it to 8 weeks + 10 days.
Initial treatment (adults)
| Regimen | Genotypes | Duration | Rating |
|---|---|---|---|
| Glecaprevir/pibrentasvir | 1–6 | 8 weeks (no cirrhosis or compensated cirrhosis) | I, A |
| Sofosbuvir/velpatasvir | 1–6 | 12 weeks (genotype 3 with cirrhosis: test for NS5A Y93H; add ribavirin if present) | I, A |
| Ledipasvir/sofosbuvir | 1, 4, 5, 6 | 12 weeks; 8 weeks for genotype 1 without cirrhosis, without HIV and RNA <6 million IU/mL | I, A / I, B |
| Elbasvir/grazoprevir | 1b, 4 (1a alternative, with RAS testing) | 12 weeks | I, A |
Adapted from AASLD/IDSA 2023 Table 1 [p. 7]
Retreatment
| Previous failure | Regimen | Duration | Rating |
|---|---|---|---|
| Sofosbuvir-based (± NS5A) | Sofosbuvir/velpatasvir/voxilaprevir (+ ribavirin for genotype 3 with cirrhosis) | 12 weeks | I, A |
| Glecaprevir/pibrentasvir (not after NS5A + protease inhibitor) | 16 weeks | IIa, B | |
| Glecaprevir/pibrentasvir | Glecaprevir/pibrentasvir + sofosbuvir + ribavirin, or SOF/VEL/VOX (+ ribavirin with cirrhosis) | 16 weeks; 12 weeks | IIa, B |
| SOF/VEL/VOX or SOF + G/P | G/P + sofosbuvir + ribavirin (16 weeks; 24 in very difficult cases), or SOF/VEL/VOX + ribavirin | 16–24 weeks | IIa, B |
Adapted from AASLD/IDSA 2023 Table 2 [p. 8]
Transplantation
- Recurrent HCV after liver transplant: glecaprevir/pibrentasvir, sofosbuvir/velpatasvir or ledipasvir/sofosbuvir for 12 weeks. [I, B · p. 11]
- HCV-negative recipient of a liver from a viraemic donor: G/P or SOF/VEL for 12 weeks, started within the first 2 weeks (ideally the first week) after transplant. [I, C · p. 11]
- Non-liver organ from a viraemic donor: G/P for 8 weeks or SOF/VEL for 12 weeks, started immediately before or on day 0. [I, C · p. 11]
Clinical pearls
- Screen every adult once and every pregnancy.
- G/P 8 weeks or SOF/VEL 12 weeks for nearly everyone.
- Missed ≥21 consecutive days after the first 4 weeks: stop and check SVR12.
- DAA failure: SOF/VEL/VOX 12 weeks.
Classes and levels of evidence
How AASLD-IDSA 2023 grades its recommendations. Adapted from AASLD-IDSA 2023 rating system [p. 1]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| Class I | Evidence and/or general agreement that a procedure or treatment is beneficial, useful and effective | |
| Class IIa | Conflicting evidence or divergent opinion; weight of evidence favours usefulness | |
| Class IIb | Conflicting evidence or divergent opinion; usefulness less well established | |
| Class III | Evidence and/or general agreement that it isn't useful and may be harmful |
| Level | Meaning |
|---|---|
| Level A | Data from multiple RCTs or meta-analyses |
| Level B | Data from a single randomised trial, non-randomised studies or observational studies |
| Level C | Consensus of expert opinion, case studies or standard of care |
The AASLD/IDSA HCV guidance rates each recommendation by class (I, IIa, IIb, III) and level of evidence (A, B, C), adapted from the ACC/AHA system.